PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2024 Earnings Call Transcript
PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.2, expectations were $-1.31. PTC Therapeutics, Inc.
Ptc Therapeutics Inc. (PTCT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 6,764,000 | $196,764,760 | -2% | 2.6% |
| 2. | 46,300,000 | $43,288,417 | 2.27% | ||
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 1,270,000 | $36,944,300 | +43% | 0.06% |
| 4. | D E Shaw D. E. Shaw | 1,225,748 | $35,657,010 | -9% | 0.03% |
| 5. | 32,500,000 | $30,354,565 | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.81 | 7,700 | 33,700 | 2023-12-12 | Filing | ||
| $32.48 | 10,000 | Director | 100,066 | 2020-03-16 | Filing | |
| $30.20 | 66,225 | Director | 1,386,594 | 2019-01-25 | Filing | |
| $13.49 | 25,000 | Director | 25,000 | 2017-05-23 | Filing | |
| $6.23 | 2,000 | Officer | 5,125 | 2016-03-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $38.24 | 20,000 | 14,500 | 2024-05-22 | Filing | ||
| $32.82 | 175 | 59,813 | 2024-05-07 | Filing | ||
| $24.89 | 3,361 | 225,807 | 2024-04-19 | Filing | ||
| $25.14 | 787 | 67,694 | 2024-04-17 | Filing | ||
| $25.14 | 1,307 | 229,168 | 2024-04-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,816,603 | $270,545,579 | 0.05% | |
| 2. | 8,800,843 | $242,551,233 | 0% | |
| 3. | 7,634,122 | $210,396,402 | 0% | |
| 4. | 7,423,970 | $204,604,613 | 3.19% | |
| 5. | 4,633,955 | $127,711,800 | 0% |
News See All
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2023 Earnings Call Transcript
PTC Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.24 EPS, expectations were $0.29.
Analysts on Wall Street Lower Ratings for These 5 Stocks
On December 19, Morgan Stanley analyst Jeffrey Hung downgraded PTC Therapeutics, Inc. (NASDAQ:PTCT) from Equalweight to Underweight, within the biotechnology industry.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2023 Earnings Call Transcript
Operator: Thank you for standing by and welcome to the PTC Therapeutics Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
PTC Therapeutics (PTCT) Lost 16% in Q2
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter. A copy of the same can be downloaded here.
Analysts on Wall Street Lower Ratings for These 5 Stocks
Federal Realty Investment Trust (NYSE:FRT) is a leading real estate company specializing in high-quality retail properties in major coastal markets from Washington, D.C., to Boston, San Francisco, and...
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q2 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by and welcome to the PTC Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by and welcome to the PTC First Quarter 2023 Financial Results Call. All participants are in a listen-only mode.
12 High Growth Healthcare Stocks to Buy
The healthcare sector proved its mettle in 2022.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2022 Earnings Call Transcript
Operator: Good day, and welcome to the PTC Therapeutics Fourth Quarter 2022 Corporate Update and Financial Results Call. At this time, all participants are in a listen-only mode.
Billionaire Hedge Funds
